Wedmont Private Capital’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$10.8M Buy
43,731
+524
+1% +$113K 0.3% 51
2026
Q1
$9.14M Buy
43,207
+1,146
+3% +$254K 0.29% 51
2025
Q4
$9.82M Sell
42,061
-3
-0% -$683 0.34% 46
2025
Q3
$9.79M Buy
42,064
+2,068
+5% +$421K 0.36% 43
2025
Q2
$7.62M Buy
39,996
+2,751
+7% +$511K 0.33% 44
2025
Q1
$6.52M Buy
37,245
+11,423
+44% +$2.22M 0.33% 46
2024
Q4
$4.52M Buy
25,822
+3,654
+16% +$672K 0.24% 60
2024
Q3
$4.29M Buy
22,168
+1,051
+5% +$196K 0.25% 57
2024
Q2
$3.6M Buy
21,117
+2,621
+14% +$434K 0.23% 63
2024
Q1
$3.15M Buy
18,496
+851
+5% +$147K 0.23% 61
2023
Q4
$2.85M Buy
17,645
+899
+5% +$131K 0.23% 62
2023
Q3
$2.5M Buy
16,746
+4,615
+38% +$677K 0.25% 64
2023
Q2
$1.65M Sell
12,131
-5,576
-31% -$818K 0.18% 82
2023
Q1
$2.86M Buy
17,707
+484
+3% +$74K 0.38% 46
2022
Q4
$2.87M Buy
17,223
+2,723
+19% +$418K 0.43% 42
2022
Q3
$1.95M Buy
14,500
+3,003
+26% +$431K 0.39% 39
2022
Q2
$1.76M Buy
11,497
+356
+3% +$54.4K 0.38% 45
2022
Q1
$1.8M Buy
11,141
+1,704
+18% +$248K 0.4% 41
2021
Q4
$1.26M Buy
+9,437
New +$1.11M 0.39% 47

Other funds holding ABBV

Wedmont Private Capital's ABBV Position: Q2 2026 in Review

Wedmont Private Capital increased its AbbVie (ABBV) stake by 1.2% in Q2 2026, buying an estimated $113K and bringing the position to 43,731 shares worth $10.8M. The position accounts for 0.3% of the portfolio, ranked #51.

Wedmont Private Capital first reported a position in ABBV in Q4 2021 and has held it in 19 quarters since. 1,476 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Wedmont Private Capital held 43,731 shares of AbbVie worth $10.8M as of Q2 2026.
  • Wedmont Private Capital bought 524 AbbVie shares in Q2 2026, an estimated $113K.
  • AbbVie made up 0.3% of Wedmont Private Capital's portfolio in Q2 2026, its #51 holding.
  • Wedmont Private Capital first reported a position in AbbVie in Q4 2021 and has held it in 19 quarters since.
  • 1,476 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Wedmont Private Capital's 13F filing for Q2 2026, filed 13 Jul 2026.